Get started
MODERNAMODERNAMODERNA

MODERNA

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

4MRNA trade ideas

WATCH MRNA Bullish Fundamental - High inflationary Macro environment / No fear sentiment - Funds Accumulation - Positive PE - PEG - Positive P/FCF - Strong Sector / Industry / Leader - Misc thoughts : looks like biotech is hot Technical - Momentum Theory Indicator - momentum bottomed and broke out - Price action formation ( falling wedge ) - Broke Trend line / neckline pressure - Under 200MA - Above POC - Under ST - Engulfing Candlestick Broke out followed through Entry idea - For members Stop loss depending on entry and risk appetite. But always set meaningful stops. " Giving up is hard. Pushing through the struggle is hard. Choose your hard " Cheers and happy trading!
NASDAQ:MRNA
by nexxtrade
analysisOn this action, we are already in an uptrend and we will not go against this trend. But we will keep a close eye on a high downtrend probability ie the breakout of the support line as well as the strong vwap followed by large volume. Indeed, it must be said, here the support line is more important than that of the resistance. But, if the resistance line also comes to be broken with force as well as the vwap followed by a large volume, it goes without saying that we would have a continuity of the said trend, namely bullish. thank you for your attention.
NASDAQ:MRNA
by PAZINI19
Moderna break of flag and retest of flag breakout area As you can clearly see the break down of the bear flag on the daily timeframe . once breakout it wanted to retest the flag breakout area by forming ascending wedge pattern which is bearish. And also on daily time frame on the top resistance area 147 to 149 , it has created rejection wick candle as we can see it is clearly rejected at the area and wedge has already breakout . the 138 139 area support need to be break in order to come down more to 132 and 126 area respectively . GOOD r/r ratio at this point . the stop loss should be break of resistance or long time frame channel. Note : please be extra careful while playing health sector therefore . i hope this chart helps .
NASDAQ:MRNA
by magarmanish528
Shooting Star on Moderna? Moderna Short Term We look to Sell at 146.42 (stop at 154.23) Preferred trade is to sell into rallies. Price action has posted a bearish Shooting Star and is negative for short-term sentiment. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. The bias is still for lower levels and we look for any gains to be limited. Our profit targets will be 122.21 and 94.19 Resistance: 150.00 / 171.76 / 187.50 Support: 120.00 / 100.00 / 66.41 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
Is Moderna Squeezing Toward a Breakout?Vaccine developer Moderna had a dramatic rally in 2021, at one point more than quadrupling from its low to high. Now, after an equally dramatic pullback, it may be flashing some interesting signs to the bulls. The first pattern on today’s chart is the $117.34 level. MRNA held that price in late March 2021 and again this month. That may suggest old support remains in effect. Second is the series of lower highs since late March 2022 as prices held those lows. The result is a descending triangle with breakout potential. Third, the falling trendline closely matches the 50-day simple moving average (SMA). MRNA closed above that line yesterday – another potential sign its direction is changing. Finally you have the recent strength in biotechnology stocks. The industry has gained about 9 percent in the last month compared with the S&P 500’s 5 percent drop. Important Information TradeStation Securities, Inc., TradeStation Crypto, Inc., and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., all operating, and providing products and services, under the TradeStation brand and trademark. You Can Trade, Inc. is also a wholly owned subsidiary of TradeStation Group, Inc., operating under its own brand and trademarks. TradeStation Crypto, Inc. offers to self-directed investors and traders cryptocurrency brokerage services. It is neither licensed with the SEC or the CFTC nor is it a Member of NFA. When applying for, or purchasing, accounts, subscriptions, products, and services, it is important that you know which company you will be dealing with. Please click here for further important information explaining what this means. This content is for informational and educational purposes only. This is not a recommendation regarding any investment or investment strategy. Any opinions expressed herein are those of the author and do not represent the views or opinions of TradeStation or any of its affiliates. Investing involves risks. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options, futures, or digital assets); therefore, you should not invest or risk money that you cannot afford to lose. Before trading any asset class, first read the relevant risk disclosure statements on the Important Documents page, found here: www.tradestation.com .
NASDAQ:MRNA
by TradeStation
1
Moderna Progress on all VaccinesThe statistics are between $184 - $219(1 Year) Its Financial Health is very strong. Why not wait till Moderna makes greater progress and finds It Resistance Again at $450 Moderna has many projects running. So if we see progress in some of the projects in the next Years, we will see a great price rise. I believe it won't be difficult to reach its older resistance again, around $450. Disclaimer: Just my Idea! Find your Trading Ideas and learn and study more!
NASDAQ:MRNALong
by TraderMentorX
Feeling sick? (Moderna)Moderna Short Term We look to Sell at 133.52 (stop at 141.88) Preferred trade is to sell into rallies. Prices expected to stall near trend line resistance. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. The bias is still for lower levels and we look for any gains to be limited. Our profit targets will be 105.41 and 94.19 Resistance: 150.00 / 171.76 / 187.50 Support: 116.00 / 100.00 / 66.41 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
Moderna - My Favorite Short Once again shorting Moderna . Sold it at $148.43 through options. It was 100% Fib retracement. CEO Bancel admits in this video on Twtter they literally throwing out vaccines, kid you not. $MRNA just threw out 30 Million vaxs : twitter.com Pfizer is now selling vaxs to the 45 poorest countries now at cost just announced in Davos at the WEF . My reasons for shorting this company are in the linked chart at the bottom. Likely get a chance to short it Monday at the open.
NASDAQ:MRNA
by Maximilianned
2
Moderna in trouble? Moderna Short Term - We look to Sell at 149.49 (stop at 160.31) Preferred trade is to sell into rallies. Closed below the 20-day EMA. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. We look to set shorts in the early trade. Our profit targets will be 123.84 and 103.50 Resistance: 150.00 / 171.76 / 187.50 Support: 125.00 / 120.00 / 104.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
2
Will the Moderna share price ever recover?The Moderna share price has fallen from its pandemic peak amid uncertain demand for its lifesaving mRNA vaccine. But will it ever recover? Moderna (NASDAQ:MRNA) shares traded for more than $450 last summer. But today the stock is trading at $136 – less than a third of its pandemic peak. The vaccine-maker stock gained massively during the pandemic. Its mRNA vaccine was favoured by governments around the world, including in the US and EU. In fact, its shot was famously touted as the Rolls-Royce of vaccines, although it was also linked with very rare cases of myocarditis that perhaps caused it to be less popular than the Pfizer vaccine by those being vaccinated. Prior to the pandemic, the Massachusetts-based firm was trading for less than $15 a share. But what comes next for Moderna? Will it return to its 2021-highs, or will it continue to fall? Why is the share price falling? Moderna only has one commercial product and that’s its lifesaving Covid-19 vaccine, Spikevax. The shot received emergency approval around the world in 2020 and 2021 and is considered one of the most effective vaccines in the fight against Covid-19. Like other vaccines, Spikevax was developed and approved on an accelerated schedule. While it is normal for vaccine development to take a decade from discovery to rollout, Spikevax was created and rolled out within a year. These exceptional circumstances propelled Moderna from a company that most people had never heard of, to a household name worldwide. Its shot was one of the first four vaccines approved for use against the virus in the West. The other vaccines included the AstraZeneca shot that was sold for cost-price by the Anglo-Swedish drugs company. However, the Moderna vaccine was sold, and continues to be, for around $20-25 a dose. In turn, this saw Moderna generate $18,4bn in 2021. The figure represents an enormous 2191% jump from 2020. In 2020, the vaccine maker saw revenues of $803m. This figure also represented a huge 1234% increase from the $60m generated in 2019. As such, we can see how the pandemic generated revenue growth in a way which is not likely to be repeated. Moderna has strong forecasts for 2022, but the future is uncertain after that. The firm, which currently has a market cap of $55bn, says it is on track to deliver $21bn in revenue in 2022. However, forecasts from then on are mixed. While the general forecast is steeply downwards. Some analysts have predicted that Moderna’s vaccine sales will dip as low as $2bn in 2024. So, investors are clearly concerned about revenue generation in years to come. And I think as we look around us, we can see that demand for Covid-19 vaccines is dropping. Not only among governments, but among normal citizens. Only elderly members of the British public are being offered fourth jabs right now and I’m not sure whether younger members of the population will be given free Covid-19 shots again. What could send the share price upwards? The less virulent nature of the Omicron strain has made vaccinations less vital. While Omicron is considerably more contagious than previous variants, it causes less severe symptoms. One thing that would send the Moderna share price soaring is the emergence of a more virulent strain, which would incentivise more vaccination. However, viruses don’t tend to evolve to become more deadly. The most successful viruses are the ones that spread, not the ones that kill their hosts. The second thing that could reverse the negative trend in the share price is the development or launch of new products with commercial potential. mRNA technology has been lauded as having the capacity to be more easily manufactured to take on diseases such as cancer. However, the majority of Moderna’s vaccines in development concern Covid-19 and other respiratory viruses. Moderna has two combined respiratory-virus vaccine candidates in its pipeline. One targets influenza and Covid-19. The other targets flu, Covid-19, and respiratory syncytial virus (RSV). Both candidates are in preclinical development. This sort of product could enhance the firm’s revenue generation capability, but it seems unlikely that such vaccines would be rolled out to whole populations. Instead, it would be targeted at the most vulnerable, probably just in time for the winter months. However, competitor Novavax is slightly closer to commercialising a similar product. Moderna also has a Cytomegalovirus (CMV) vaccine in phase three trials. CMV is related to the herpes virus that causes cold sores and chickenpox. However, once you have the virus, you retain it for life. It can cause serious health problems in some babies who get the virus before birth and in adults with weakened immune systems. The biotech firm is also developing a Zika vaccine and a personalized cancer vaccine (PCV). The PCV is in phase two trials and such vaccines, if successful, are likely to be very lucrative. The disease is one of the biggest killers worldwide and treatment can be very costly. Moderna is also working on a HIV vaccine. However, many of Moderna’s vaccines are still some distance from commercialisation. Reaching commercialisation can take a decade or longer. Valuation Because of the uncertain future, Moderna looks very cheap by some metrics. The biotech firm has a price-to-earnings (P/E) ratio of just four, based on its profits over the past 12 months. It also has a price-to-sales ratio of just 2.4. Moderna’s valuation is quite unique in many respects. Growth stocks tend to be expensive as they’re partially valued on future revenue potential rather than their current earnings. However, Moderna growth appears to have been short-lived, and it seems unlikely that such revenue growth can be repeated in the future. With peak demand for Covid-19 vaccines likely past, an increase in the share price, at least in the short term, seems unlikely. However, I don’t see the stock’s share price falling much further. One forecast suggests that Moderna’s profits could fall to $2bn in 2024. If the market cap remained the same as it is today, $2bn in profit would give Moderna a P/E ratio of around 27 in 2024. That’s still expensive by some metrics, but biotech firms tend to trade at a premium given their valuation reflects future earnings potential. And Moderna clearly has some potential beyond its current Covid jab.
NASDAQ:MRNALong
by JamesFox_MentorFinance
3